FierceBiotechOriginal article
{"a":[{"_":"Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey","$":{"href":"/biotech/expedition-lands-115m-series-b-advance-phase-2-copd-trial","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Expedition Therapeutics secured an oversubscribed $115 million series B financing round backed by Sanofi to advance its lead DPP1 inhibitor through phase 2 trials for COPD treatment.
Clinical Trial Data
Phase
2
Importance:6/10
Sentiment:
0.60
financingseries_BCOPDDPP1_inhibitorphase_2
Related Companies
Read the original article
Published by FierceBiotech on August 4, 2026 12:52 PM